Arrowhead (ARWR) Presents New Data Showing Sustained Host Response in HBV Patients Following RNAi Therapy

December 6, 2017 8:46 AM

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) presented new data from the company’s Phase 2 clinical study in patients that received multiple ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found